Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Drops Phase II Diabetes Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Compound fails to measure up to exisiting treatments, firm says.

You may also be interested in...



Actos Patent Expiry Fuels Takeda’s Drive For Deals – Licensing Exec

During BIO-Asia 2007 in Tokyo, Takeda’s head of licensing outlines the strategy behind the company’s deal with Affymax.

Actos Patent Expiry Fuels Takeda’s Drive For Deals – Licensing Exec

During BIO-Asia 2007 in Tokyo, Takeda’s head of licensing outlines the strategy behind the company’s deal with Affymax.

Actos Patent Expiry Fuels Takeda's Drive For Deals - Licensing Exec

Takeda is looking to partner with companies owning late-stage compounds in an effort to replace revenue that will likely be lost following U.S. patent expiry of its blockbuster type 2 diabetes treatment Actos (pioglitazone), according to General Manager of Global Licensing & Business Development Hiroaki Ogata

Related Content

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel